Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab versus standard consolidation chemotherapy in pediatric high-risk first relapse B-precursor ALL
NL-OMON53052Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Blinatumomab consolidation with Standard of care consolidation chemotherapy (2 arms). Primary endpoint: Event-free survival. Started Feb 2017; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON53052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53052.